Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, AutologousTransplantation, HomologousHematopoietic Stem Cell MobilizationTransplantation ConditioningHematologic NeoplasmsGranulocyte Colony-Stimulating FactorLeukapheresisMelphalanGraft vs Host DiseaseAntigens, CD34Blood Component RemovalCombined Modality TherapyStem Cell TransplantationMyeloablative AgonistsCyclophosphamideHematopoietic Stem CellsMultiple MyelomaBone Marrow TransplantationBusulfanAntineoplastic Combined Chemotherapy ProtocolsGraft SurvivalTreatment OutcomeLymphoma, Non-HodgkinStem CellsRemission InductionRecurrenceEtoposideThiotepaAntineoplastic Agents, AlkylatingCord Blood Stem Cell TransplantationTissue DonorsTransplantation ChimeraWhole-Body IrradiationHematopoiesisSalvage TherapyCarmustineDisease-Free SurvivalIfosfamideHistocompatibilityRetrospective StudiesHistocompatibility TestingCytophagocytosisVincristineSurvival RateHodgkin DiseaseCytarabineAmyloidosisSurvival AnalysisVidarabineTime FactorsImmunosuppressive AgentsNeoplasmsInfectionLeukemia, Myeloid, AcuteLeukemiaBlood CellsBlood Cell CountPlatelet CountPOEMS SyndromeGraft vs Leukemia EffectTransplantation, IsogeneicUnrelated DonorsDoxorubicinFollow-Up StudiesLymphoma, T-CellLiver TransplantationMyelodysplastic SyndromesBone Marrow PurgingCytomegalovirus InfectionsLymphomaRecombinant ProteinsCarboplatinPrednisoneAnemia, AplasticHLA AntigensDexamethasoneHematologic DiseasesAntineoplastic AgentsProspective StudiesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveGraft vs Tumor EffectFeasibility StudiesLymphocyte DepletionT-LymphocytesImmunophenotypingCyclosporineSiblingsFatal OutcomePrecursor Cell Lymphoblastic Leukemia-LymphomaBone MarrowBlood DonorsLeukocytes, MononuclearFlow CytometryImmunosuppressionTransplantation ImmunologyCell SeparationMesenchymal Stem Cell TransplantationBone Marrow Cells